TLP
TARA icon

Tri Locum Partners’s Protara Therapeutics TARA Stock Holding History

Tri Locum Partners’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-39,225
Closed -$950K – 71
2020
Q4 		$950K Buy
+39,225
New +$846K 0.35% 36

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Tri Locum Partners's TARA Position: Q1 2021 in Review

Tri Locum Partners sold out of Protara Therapeutics (TARA) in Q1 2021, closing a stake of 39,225 shares — an estimated $950K sold.

Tri Locum Partners first reported a position in TARA in Q4 2020 and held it in 1 quarter. The position peaked at $950K in Q4 2020. 49 funds tracked by Wall St. Rank hold TARA as of Q1 2021.

  • Tri Locum Partners reported no remaining Protara Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Tri Locum Partners sold 39,225 Protara Therapeutics shares in Q1 2021, an estimated $950K.
  • Tri Locum Partners first reported a position in Protara Therapeutics in Q4 2020 and held it in 1 quarter.
  • Tri Locum Partners's Protara Therapeutics position peaked at $950K in Q4 2020.
  • 49 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2021.

Based on Tri Locum Partners's 13F filing for Q1 2021, filed 17 May 2021.